Turn recording back on
FDG PET-CT demonstration of metastatic neuroendocrine tumor of prostate.
Liu Y.
World J Surg Oncol. 2008 Jun 19;6:64.
PMID: 18565231 [PubMed - indexed for MEDLINE]
Related Articles Free article in PMC
Positron emission tomography for prostate, bladder, and renal cancer.
Schöder H, Larson SM.
Semin Nucl Med. 2004 Oct;34(4):274-92. Review.
PMID: 15493005 [PubMed - indexed for MEDLINE]
Related Articles
Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG.
Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, Dickson J, Caplin M, Ell PJ.
Cancer. 2008 Jun;112(11):2447-55.
PMID: 18383518 [PubMed - indexed for MEDLINE]
Positron emission tomography and bone metastases.
Fogelman I, Cook G, Israel O, Van der Wall H.
Semin Nucl Med. 2005 Apr;35(2):135-42. Review.
PMID: 15765376 [PubMed - indexed for MEDLINE]
[18F]Fluorodeoxyglucose positron emission tomography surveillance of hepatic metastases from prostate cancer following radiofrequency ablation: a case report.
Ludwig V, Hopper OW, Martin WH, Kikkawa R, Delbeke D.
Am Surg. 2003 Jul;69(7):593-8.
PMID: 12889623 [PubMed - indexed for MEDLINE]
The roles of PET and PET/CT in the diagnosis and management of prostate cancer.
Takahashi N, Inoue T, Lee J, Yamaguchi T, Shizukuishi K.
Oncology. 2007;72(3-4):226-33. Epub 2008 Jan 7. Review.
PMID: 18176088 [PubMed - indexed for MEDLINE]
Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients.
Fricke E, Machtens S, Hofmann M, van den Hoff J, Bergh S, Brunkhorst T, Meyer GJ, Karstens JH, Knapp WH, Boerner AR.
Eur J Nucl Med Mol Imaging. 2003 Apr;30(4):607-11. Epub 2003 Feb 13.
PMID: 12589476 [PubMed - indexed for MEDLINE]
The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer.
Oyama N, Akino H, Suzuki Y, Kanamaru H, Sadato N, Yonekura Y, Okada K.
Jpn J Clin Oncol. 1999 Dec;29(12):623-9.
PMID: 10721945 [PubMed - indexed for MEDLINE]
Positron emission tomography for radiation treatment planning.
Grosu AL, Piert M, Weber WA, Jeremic B, Picchio M, Schratzenstaller U, Zimmermann FB, Schwaiger M, Molls M.
Strahlenther Onkol. 2005 Aug;181(8):483-99. Review.
PMID: 16044216 [PubMed - indexed for MEDLINE]
Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site.
Pelosi E, Pennone M, Deandreis D, Douroukas A, Mancini M, Bisi G.
Q J Nucl Med Mol Imaging. 2006 Mar;50(1):15-22.
PMID: 16557200 [PubMed - indexed for MEDLINE]
Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer.
Nuñez R, Macapinlac HA, Yeung HW, Akhurst T, Cai S, Osman I, Gonen M, Riedel E, Scher HI, Larson SM.
J Nucl Med. 2002 Jan;43(1):46-55.
PMID: 11801702 [PubMed - indexed for MEDLINE]
Neuroendocrine tumor imaging: can 18F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior?
Pasquali C, Rubello D, Sperti C, Gasparoni P, Liessi G, Chierichetti F, Ferlin G, Pedrazzoli S.
World J Surg. 1998 Jun;22(6):588-92.
PMID: 9597933 [PubMed - indexed for MEDLINE]
Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer.
Price DT, Coleman RE, Liao RP, Robertson CN, Polascik TJ, DeGrado TR.
J Urol. 2002 Jul;168(1):273-80.
PMID: 12050555 [PubMed - indexed for MEDLINE]
Multimodality approach of perioperative 18F-FDG PET/CT imaging, intraoperative 18F-FDG handheld gamma probe detection, and intraoperative ultrasound for tumor localization and verification of resection of all sites of hypermetabolic activity in a case of occult recurrent metastatic melanoma.
Povoski SP, Hall NC, Martin EW Jr, Walker MJ.
World J Surg Oncol. 2008 Jan 10;6:1.
PMID: 18186915 [PubMed - indexed for MEDLINE]
Improved staging with pretreatment positron emission tomography/computed tomography in low rectal cancer.
Gearhart SL, Frassica D, Rosen R, Choti M, Schulick R, Wahl R.
Ann Surg Oncol. 2006 Mar;13(3):397-404. Epub 2006 Jan 30.
PMID: 16485158 [PubMed - indexed for MEDLINE]
Whole-body FDG positron emission tomographic imaging for staging esophageal cancer comparison with computed tomography.
Meltzer CC, Luketich JD, Friedman D, Charron M, Strollo D, Meehan M, Urso GK, Dachille MA, Townsend DW.
Clin Nucl Med. 2000 Nov;25(11):882-7.
PMID: 11079584 [PubMed - indexed for MEDLINE]
Lymph node staging of gastric cancer using (18)F-FDG PET: a comparison study with CT.
Yun M, Lim JS, Noh SH, Hyung WJ, Cheong JH, Bong JK, Cho A, Lee JD.
J Nucl Med. 2005 Oct;46(10):1582-8.
PMID: 16204706 [PubMed - indexed for MEDLINE]
[Evaluation of prostate cancer using FDG-PET]
Kanamaru H, Oyama N, Akino H, Okada K.
Hinyokika Kiyo. 2000 Nov;46(11):851-3. Japanese.
PMID: 11193311 [PubMed - indexed for MEDLINE]
Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours.
Adams S, Baum R, Rink T, Schumm-Dräger PM, Usadel KH, Hör G.
Eur J Nucl Med. 1998 Jan;25(1):79-83.
PMID: 9396878 [PubMed - indexed for MEDLINE]
Monitoring the efficacy of iodine-131-MIBG therapy using fluorine-18-FDG-PET.
Menzel C, Graichen S, Berner U, Risse JH, Diehl M, Döbert N, Hamscho N, Grünwald F.
Acta Med Austriaca. 2003;30(2):37-40.
PMID: 12752086 [PubMed - indexed for MEDLINE]